These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8782665

  • 1. Structure-activity relationship of 17 structural analogues of n-butyric acid upon c-myc expression.
    Rottleb C, Hall C, Bornkamm GW, Polack A.
    Int J Cancer; 1996 Sep 04; 67(5):724-9. PubMed ID: 8782665
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 4. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A, Strobl L, Feederle R, Schweizer M, Koch E, Eick D, Wiegand H, Bornkamm GW.
    Oncogene; 1991 Nov 01; 6(11):2033-40. PubMed ID: 1945409
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I, Jain V, Bhatia K.
    Semin Cancer Biol; 1992 Oct 01; 3(5):285-95. PubMed ID: 1335792
    [Abstract] [Full Text] [Related]

  • 7. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA, Chang L, Buzby JS, Suen Y, Cairo MS.
    Leukemia; 1996 Dec 01; 10(12):1980-9. PubMed ID: 8946941
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.
    Cancer Res; 1989 Jun 15; 49(12):3235-41. PubMed ID: 2497974
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular biology of Burkitt's lymphoma.
    Hecht JL, Aster JC.
    J Clin Oncol; 2000 Nov 01; 18(21):3707-21. PubMed ID: 11054444
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
    Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, Bornkamm GW.
    Int J Cancer; 2007 Apr 01; 120(7):1387-95. PubMed ID: 17211884
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

  • 17. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME, Lemieux R, Jung D.
    J Cell Physiol; 2005 Apr 15; 203(1):277-85. PubMed ID: 15468060
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
    Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE.
    Ann Hematol; 2014 Jun 15; 93(6):983-93. PubMed ID: 24577510
    [Abstract] [Full Text] [Related]

  • 19. The role of immunoglobulin kappa elements in c-myc activation.
    Hörtnagel K, Mautner J, Strobl LJ, Wolf DA, Christoph B, Geltinger C, Polack A.
    Oncogene; 1995 Apr 06; 10(7):1393-401. PubMed ID: 7731690
    [Abstract] [Full Text] [Related]

  • 20. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M, Neuberger MS.
    Oncogene; 2000 Jul 13; 19(30):3404-10. PubMed ID: 10918597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.